Drugs / Selitrectinib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04771390 | Feb → May 2021 | NTRK fusion positive cancer | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04275960 | Feb → Oct 2020 | NTRK fusion positive cancer | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03215511 | Jul 2017 → Apr 2022 | NTRK fusion positive cancer | Bayer | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03206931 | — | NTRK fusion positive cancer | Bayer | No longer available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-02-15 | Bayer | Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195) bayer.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selitrectinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03206931 ↗ |
| Known as | BAY 2731954 | “Treatment was switched to the investigational next-generation TRK inhibitor selitrectinib (BAY 2731954, LOXO-195) 100 mg twice daily.” PMID 31605106 ↗ Dec 20194“Selitrectinib (BAY2731954) Adult tablet” NCT04771390 ↗ “Selitrectinib (BAY2731954)” NCT03215511 ↗ “Selitrectinib (BAY2731954)” NCT04275960 ↗ “Selitrectinib (BAY2731954)” NCT03206931 ↗ |
| Known as | LOXO-195 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297627 ↗ |
| Action | Inhibit | “The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth.” NCT03215511 ↗ |
| Modality | Small molecule | — CHEMBL4297627 ↗ |
| Route | Oral | “oral selitrectinib” NCT03215511 ↗ |
| Target | NTRK1 | “This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3)....” NCT03215511 ↗ |
| Target | NTRK2 | “This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3)....” NCT03215511 ↗ |
| Target | NTRK3 | “This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3)....” NCT03215511 ↗ |